Revumenib

Products

Inquiry

Cat. No.: IBDI-435858

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target	Epigenetic Reader Domain
Molecular Weight	630.82
Appearance	Solid
Synonyms	SNDX-5613
SMILES	O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[[email protected]]5CC[[email protected]](NS(=O)(CC)=O)CC5)CC4)C3
Purity	99.88%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years; 4°C/2 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.

! For research use only, not intended for any clinical use.